Table 1.
The distribution of clinicopathological characteristics and their associations with nestin status in the whole series (n=3641)
| Clinico-pathological characteristic | Nestin negative (<1%) (n=3270) | Nestin positive (≥ 1%) (n=371) | Total (n=3641) | P-value |
|---|---|---|---|---|
| Age, years* | <0.001 | |||
| <60 | 1444 (50%) | 215 (63%) | 1659 (51%) | |
| ≥ 60 | 1451 (50%) | 124 (37%) | 1575 (49%) | |
| Tumor Size, cm | 0.2 | |||
| ≤2 | 1521 (53%) | 166 (49%) | 1687 (52%) | |
| >2 | 1361 (47%) | 172 (51%) | 1533 (48%) | |
| Tumor grade* | ||||
| 1–2 | 1347 (49%) | 78 (24%) | 1425 (46%) | <0.001 |
| 3 | 1428 (51%) | 251 (76%) | 1679 (54%) | |
| Lymph nodes* | 0.005 | |||
| Negative | 1797 (55%) | 232 (63%) | 2029 (56%) | |
| Positive | 1459 (45%) | 137 (37%) | 1596 (44%) | |
| Lymphovascular Invasion | 0.06 | |||
| Negative | 1492 (54%) | 196 (59%) | 1412 (46%) | |
| Positive | 1278 (46%) | 134 (41%) | 1688 (54%) | |
| ER status (by IHC)* | <0.001 | |||
| Negative | 678 (23%) | 218 (64%) | 896 (28%) | |
| Positive | 2207 (77%) | 120 (36%) | 2327 (72%) | |
| ER clinical status (by DCC)* | <0.001 | |||
| Negative (0–9 fmol/mg) | 448 (16%) | 184 (56%) | 632 (20%) | |
| Positive (>10 fmol/mg) | 2381 (84%) | 142 (44%) | 2523 (80%) | |
| ER positivity score (by IHC)* | <0.001 | |||
| 0 | 731 (27%) | 229 (69%) | 960 (31%) | |
| 1%–10% | 502 (18%) | 35 (11%) | 537 (18%) | |
| >10% | 1496 (55%) | 65 (20%) | 1561 (51%) | |
| HER-2 Status | ||||
| Negative | 2455 (87%) | 293 (88%) | 2748 (87%) | 0.6 |
| Positive | 383 (13%) | 42 (12%) | 425 (13%) | |
| KI67* | <0.001 | |||
| <14% | 1511 (57%) | 94 (30%) | 1605 (54%) | |
| ≥14% | 1141 (43%) | 216 (70%) | 1357 (46%) | |
| Systemic treatment* | <0.001 | |||
| No systemic therapy | 1351 (41%) | 190 (51%) | 1541 (42%) | |
| Tamoxifen only; no chemotherapy | 1132 (35%) | 56 (15%) | 1188 (33%) | |
| Chemotherapy only; no hormonal | 539 (17%) | 105 (28%) | 644 (18%) | |
| Chemotherapy + hormonal | 234 (7%) | 19 (5%) | 253 (7%) | |
| CK5* | <0.001 | |||
| Negative | 2418 (94%) | 209 (69%) | 2627 (91%) | |
| Positive | 156 (6%) | 93 (31%) | 249 (9%) | |
| EGFR* | <0.001 | |||
| Negative | 2363 (90%) | 173 (58%) | 2536 (87%) | |
| Positive | 259 (10%) | 127 (42%) | 386 (13%) | |
| Basal Subtype Groups* | ||||
| Core basal | 164 (6%) | 132 (40%) | 296 (10%) | <0.001 |
| Non-Core basal | 2632 (94%) | 200 (60%) | 2832 (90%) | |
| Triple Negative | 340 (12%) | 181 (55%) | 521 (17%) | <0.001 |
| Non-Triple negative | 2456 (88%) | 151 (45%) | 2607 (83%) |
*
Indicates significant difference, P≤0.05
ER: Estrogen receptor; IHC: Immunohistochemical; DCC: Dextran-coated charcoal of ligand binding assay; HER2: Human epidermal growth factor receptor-2; CK5: Cytokeratin 5; EGFR: Epidermal growth factor receptor.